Oncotarget

Reviews:

PD1 signal transduction pathways in T cells

Hugo Arasanz, Maria Gato-Cañas, Miren Zuazo, Maria Ibañez-Vea, Karine Breckpot, Grazyna Kochan and David Escors _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:51936-51945. https://doi.org/10.18632/oncotarget.17232

Metrics: PDF 8992 views  |   HTML 12163 views  |   ?  


Abstract

Hugo Arasanz1,*, Maria Gato-Cañas1,*, Miren Zuazo1,*, Maria Ibañez-Vea1,*, Karine Breckpot3, Grazyna Kochan1 and David Escors1,2

1Immunomodulation Group, Navarrabiomed-Biomedical Research Centre, IdISNA, Pamplona, Spain

2Rayne Institute, Division of Infection and Immunity, University College London, London, United Kindom

3Laboratory of Molecular and Cellular Therapy Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium

*These authors have contributed equally to this work

Correspondence to:

David Escors, email: [email protected]

Grazyna Kochan, email: [email protected]

Keywords: PD-L1, PDL1, PD1, B7-H1, cancer

Received: February 28, 2017     Accepted: March 24, 2017     Published: April 19, 2017

ABSTRACT

The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17232